Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Next Previous
Trial Profile

A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Bronchiectasis; Pseudomonal infections
  • Focus Therapeutic Use
  • Acronyms iBEST-1
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 13 Sep 2023 Results determining changes in the antimicrobial resistome and airway microbiota followingtreatment with tobramycin inhalation powder (TIP) or placebo by extracting DNA from sputum collected at baseline and at day 29 from this study, presented at the 33rd Annual Congress of the European Respiratory Society
  • 27 Aug 2020 Results determining the efficacy of a safe and well-tolerated dose and regimen of tobramycin inhalation powder (TIP) on Pseudomonas aeruginosa (Pa) sputum density in patients with bronchiectasis published in the European Respiratory Journal
  • 20 May 2020 Primary endpoint (P. aeruginosa density in sputum) has been met, as per results presented at the 116th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top